Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 29,612 Shares

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 29,612 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total value of $266,211.88. Following the sale, the chief executive officer owned 148,486 shares in the company, valued at $1,334,889.14. The trade was a 16.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Personalis Trading Down 12.3%

Shares of PSNL stock traded down $1.07 during mid-day trading on Wednesday, reaching $7.66. The stock had a trading volume of 2,105,071 shares, compared to its average volume of 1,067,993. The stock’s 50-day moving average price is $7.18 and its two-hundred day moving average price is $6.01. The firm has a market capitalization of $679.29 million, a PE ratio of -5.98 and a beta of 1.92. Personalis, Inc. has a 52-week low of $2.83 and a 52-week high of $10.95.

Personalis (NASDAQ:PSNL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The firm had revenue of $14.50 million during the quarter, compared to analyst estimates of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities research analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current year.

Institutional Investors Weigh In On Personalis

Hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc purchased a new position in Personalis during the 2nd quarter worth approximately $30,000. Ameritas Investment Partners Inc. purchased a new position in Personalis during the second quarter worth $34,000. BNP Paribas Financial Markets lifted its stake in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares during the period. Alpha Wealth Funds LLC purchased a new stake in shares of Personalis during the 2nd quarter valued at $66,000. Finally, Farther Finance Advisors LLC purchased a new stake in Personalis during the 3rd quarter worth $66,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PSNL. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Wednesday, October 8th. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of Personalis in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $8.50 price target on shares of Personalis in a research note on Monday, September 8th. Finally, BTIG Research lifted their price target on Personalis from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Personalis currently has a consensus rating of “Moderate Buy” and an average price target of $9.08.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.